98%
921
2 minutes
20
Background: Pre-exposure prophylaxis (PrEP) use among populations most vulnerable to HIV as identified in the national HIV prevention goals is not fully known. This systematic review assessed trends of lifetime self-reported PrEP use and disparities among key populations.
Methods: We used the CDC HIV/AIDS Prevention Research Synthesis cumulative database of electronic and manual searches in MEDLINE, CINAHL, EMBASE, and PsycINFO from 2000 to 2019 to identify English-language primary studies reporting PrEP use. Two reviewers independently screened citations, extracted data, and assessed the risk of bias with the modified Newcastle-Ottawa Scale. We estimated pooled proportions and crude/adjusted odds ratio.
Results: We identified 95 eligible studies including 95,854 US-based survey respondents. A few studies (6.3%) focused on persons who inject drugs. In 2015-2017, men who have sex with men (MSM) had highest proportion of individuals who used PrEP over their lifetime [13.9% (95% confidence interval: 8.8 to 21.1), k (number of surveys) = 49] followed by Hispanic/Latinos [11.5 (7.1 to 18.1), 12], transgender women [11.2 (5.8 to 20.6), 5], and blacks [9.9 (8.3 to 11.8), 18]. Odds of PrEP use increased by 34%/year [odds ratio = 1.34/year (95% confidence interval: 1.09 to 1.64)] and significantly increased over time among MSM [1.53/year (1.21-1.93)] and blacks [1.44 (1.13-1.83)]. People in the Southern United States [9.9 (4.7-19.7), 8] and youth [7.3 (4.7-11.2), 8] had lower rates and did not demonstrate growth [0.94 (0.29-3.18); 0.82 (0.43-1.55)]. Odds of reporting lifetime PrEP use was twice [2.07 (1.27-3.38)] as great among MSM than non-MSM.
Conclusions: Proportions of PrEP use in published surveys have been growing, but remain low for people in the Southern United States and youth, and understudied in persons who inject drugs. Limitations include few studies in certain years, whereas strengths include a large number of respondents. Culturally tailored approaches targeting vulnerable populations are essential in increasing PrEP use to reduce disparities in HIV acquisition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022293 | PMC |
http://dx.doi.org/10.1097/QAI.0000000000002345 | DOI Listing |
Arthritis Rheumatol
September 2025
Washington DC Veterans Affairs Medical Center; Georgetown University, Washington, DC, USA.
Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.
J Org Chem
September 2025
Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon EN11 9FH, United Kingdom.
Sulfur(VI) fluoride exchange (SuFEx) compounds are gaining increasing attention due to their various applications. We present the Diels-Alder reaction of ethenesulfonyl fluoride and analogues to rapidly access cyclic and bicyclic SuFEx derivatives in moderate to good yields. These derivatives have been shown to be useful intermediates in a variety of synthetic transformations to expand the toolkit for the preparation of cyclic aliphatic sulfonyl fluorides.
View Article and Find Full Text PDFNano Lett
September 2025
School of Chemistry and Materials Science, Hunan Agricultural University, Changsha 410128, China.
Passivating detrimental defects is essential for improving perovskite solar cells (PSCs) performance. While hydrogen interstitials are often considered harmful, their role in defect passivation remains unclear. Using nonadiabatic molecular dynamics, we uncover a self-passivation mechanism between hydrogen (H) and bromine (Br) interstitials in all-inorganic CsPbBr perovskites.
View Article and Find Full Text PDFMol Cancer Ther
September 2025
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor down-regulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor.
View Article and Find Full Text PDFDrug Alcohol Rev
September 2025
The Prescription Drug Misuse Education and Research (PREMIER) Center, University of Houston, Houston, Texas, USA.
Introduction: Buprenorphine is effective for opioid use disorder (OUD), yet adherence remains suboptimal. This study aimed to identify adherence trajectories, explore their predictors, and assess their association with opioid overdose risk and healthcare costs.
Methods: A retrospective cohort study was conducted using the Merative MarketScan Commercial Database, which includes a nationally representative sample of individuals with private, employer-sponsored health insurance in the United States.